Navigation Links
CV Therapeutics Announces Topline MERLIN TIMI-36 Results

- Full study results will be presented at the American College of Cardiology's Scientific Session -

PALO ALTO, Calif., March 06, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that an analysis of unblinded data from the MERLIN TIMI-36 study of ranolazine shows there was no adverse trend in death or arrhythmias in patients on ranolazine. The study did not meet the primary efficacy endpoint.

In accordance with the company's special protocol assessment agreement with the U.S. Food and Drug Administration (FDA), the company believes that the data could support expansion of the existing Ranexa(R) (ranolazine extended-release tablets) indication to include first line angina.

Complete data are scheduled to be presented as a late breaking clinical trial on Tuesday, March 27 at 8:50 a.m. central time during the 2007 of Cardiology Scientific Session in New Orleans.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in approximately 6,500 patients with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERLIN TIMI-36 have been studied in previous Phase 3 clinical trials.

Currently, Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

About Angina

Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain. Approximately 8.9 million people in the United States have chronic angina, and 400,000 new cases are diagnosed annually, according to the American Heart Association. Ranexa has anti-ischemic effects which do not depend on changes in heart rate or blood pressure.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the

discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for asthma and other conditions. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forwa rd-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the quarter ended December 31, 2006. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

CONTACT: Investor and Media Contact: John Bluth, Senior Director,Corporate Communications and Investor Relations, CV Therapeutics, Inc.,+1-650-384-8850, or Investor Contact: Dahlia Bailey, Senior InvestorRelations Manager, CV Therapeutics, Inc., +1-650-384-8585

Web site: http://www.cvt.com/

Ticker Symbol: (NASDAQ-NMS:CVTX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... YORK , Jan. 16, 2017 ... Densitometers Market Outlook to 2022", provides key market data ... provides value, in millions of US dollars, volume (in ... Dual Energy X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). ... shares data for each of these market segements, and ...
(Date:1/16/2017)... 16, 2017 The global pacemaker market is ... to a new report by Grand View Research, Inc. ... availability of medical coverage is a key driving factor ... enhancements in these devices are supporting the expansion of ... is a high-impact growth rendering driver for this market. ...
(Date:1/16/2017)...   The Harrington Discovery Institute at ... , has announced the 2017 recipients of Harrington ... physician-scientists whose research shows promise to advance the ... Institute – part of The Harrington Project for ... academic medicine: to advance early breakthroughs into the ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... IL (PRWEB) , ... January 16, 2017 , ... ... audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the ... Center in Las Vegas, Booth #2809. The SHOT Show is the shooting, hunting ...
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for a substance ... released by Serenity Recovery, a holistic treatment center for addiction located in Marne, MI. ... and testimonials from patients and staff that visited the 2016 Recovery Palooza support event ...
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... ... January 16, 2017 , ... Specialty Technical Publishers (STP) ... Audit Protocol Consortium (IAPC) EHS audit protocol for Singapore . Leading companies ... their EHS regulatory obligations and rapidly collect, share, archive, and export audit findings ...
Breaking Medicine News(10 mins):